Corteva (CTVA) to Release Earnings on Tuesday

Key Points

• Corteva (CTVA) will release Q1 2026 results after the market close on Tuesday, May 5, with analysts forecasting $1.14 EPS and $4.642 billion in revenue; the company has set FY2026 guidance at $3.450–$3.700 EPS and will hold a conference call Wednesday, May 6 at 9:00 AM ET.
• In its last report on Feb. 3 Corteva posted $0.22 EPS—meeting estimates—but revenue of $3.91 billion missed expectations of $4.23 billion; analysts still project about $4 EPS for the current and next fiscal years.
• Shares trade near $79.53 (1‑year range $60.53–$85.63) with a market cap of ~$53.4B, a PE of ~50.3, an annualized dividend of $0.72 (0.9% yield), and an average analyst rating of "Moderate Buy" with a $85.19 price target.

Corteva (NYSE:CTVA - Get Free Report) is expected to release its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Corteva to post earnings of $1.14 per share and revenue of $4.6424 billion for the quarter. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 9:00 AM ET.

Corteva (NYSE:CTVA - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.22. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business had revenue of $3.91 billion during the quarter, compared to analysts' expectations of $4.23 billion. During the same period in the prior year, the firm posted $0.32 EPS. Corteva's quarterly revenue was down 1.7% compared to the same quarter last year. On average, analysts expect Corteva to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Corteva Trading Down 0.3%

Shares of CTVA opened at $79.53 on Tuesday. Corteva has a 1 year low of $60.53 and a 1 year high of $85.63. The company has a current ratio of 1.43, a quick ratio of 0.96 and a debt-to-equity ratio of 0.07. The stock has a 50 day simple moving average of $80.19 and a 200-day simple moving average of $71.82. The stock has a market cap of $53.39 billion, a PE ratio of 50.34, a PEG ratio of 2.74 and a beta of 0.68.

Corteva Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 16th. Stockholders of record on Monday, March 2nd were issued a $0.18 dividend. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. Corteva's dividend payout ratio is presently 45.57%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CTVA. CICC Research increased their target price on Corteva from $70.00 to $80.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Wolfe Research lifted their price objective on Corteva from $81.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. Wells Fargo & Company lifted their price objective on Corteva from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Tuesday, April 21st. JPMorgan Chase & Co. downgraded Corteva from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $75.00 to $77.00 in a research report on Thursday, February 5th. Finally, Bank of America lifted their price objective on Corteva from $80.00 to $82.00 and gave the company a "buy" rating in a research report on Thursday, January 8th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $85.19.

Insider Transactions at Corteva

In other Corteva news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. The trade was a 50.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.15% of the company's stock.

Institutional Investors Weigh In On Corteva

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPL Wealth Management LLC acquired a new stake in shares of Corteva in the 3rd quarter valued at $25,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Corteva in the 4th quarter valued at $27,000. Bank of Jackson Hole Trust acquired a new stake in shares of Corteva in the 4th quarter valued at $28,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Corteva in the 3rd quarter valued at $33,000. Finally, Binnacle Investments Inc increased its stake in shares of Corteva by 54.7% in the 2nd quarter. Binnacle Investments Inc now owns 512 shares of the company's stock valued at $38,000 after buying an additional 181 shares during the period. 81.54% of the stock is owned by institutional investors and hedge funds.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.